Trial
NCT07213960
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Phase IISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
Apellis Pharmaceuticals, Inc.
Collaborators
—
Condition
FSGS
Intervention
APL2
Why stopped
Study temporarily suspended due to company acquisition and ongoing strategic evaluation, with recruitment challenges including screening failures
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-22